Little Rock, Arkansas 72202

  • Asthma


The primary objective of this study is to determine ex vivo the amount of fluticasone deposited onto a filter (delivered dose) interposed between the OptiChamber Diamond Valved Holding Chamber (VHC) mouthpiece and the subject's mouth during coordinated and uncoordinated actuation/inhalation maneuver.


Inclusion Criteria: - • Asthmatic children between the ages of 5 and 8 followed at Arkansas Children's Hospital. - The subjects must be available to complete the study. - The subject's parent(s) and/or the subject's legal guardian must provide written informed consent to participate in the study. - The subject must provide assent when older than 7 years old. - The subjects should have used a pMDI VHC previously and be able to use a VHC with mouthpiece. - The subjects should have been prescribed fluticasone or another inhaled corticosteroid delivered via a pMDI VHC combination. - Clinically stable asthma. - Cooperative, i.e., subject should be able to follow and understand instructions. - The subject must satisfy the study investigator about his/her fitness to participate in the study. Exclusion Criteria: - Clinically significant respiratory disease in the previous 4 weeks. - Participation in any other clinical trial in the previous 4 weeks. - Lack of cooperation, subject cannot follow and understand instructions.



Primary Contact:

Principal Investigator
Ariel Berlinski, MD
University of Arkansas

Backup Contact:


Location Contact:

Little Rock, Arkansas 72202
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: June 13, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.